The In Vivo Shuttle LNP kit series, developed with Hanz Biotech’s proprietary LNP technology, is designed for efficient, targeted, and biocompatible nucleic acid delivery in vivo. The platform supports both general-purpose delivery and organ-specific targeting, covering the liver, spleen, lungs, and skin.

It also includes solutions for immune cell targeting—such as macrophages, dendritic cells, and T cells—meeting the needs of immunotherapy and vaccine research. A dedicated gene editing kit optimized for CRISPR/Cas9 (Cas9 mRNA + gRNA) is also available, enabling precise in vivo genome modification.

With its modular and standardized design, the series supports a wide range of applications including gene therapy, vaccine development, and functional genomics.